Specialty Pharmacy

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

At the ESMO Congress 2019, Eileen O'Reilly, MD, from Memorial Sloan Kettering Cancer Center, discussed the common themes among emerging therapies in the advanced pancreatic cancer setting.

Ron Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.

Patients with non-Hodgkin lymphoma were more likely to discontinue treatment early when prescribed rituximab by physicians who had less experience with the drug.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq., discusses challenges in launching biosimilars after they've been approved.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Effective December 31, 2019, Amgen’s 60% annual list price cut for evolocumab (Repatha) will be fully implemented.

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.

Top news of the day from across the health care landscape.

The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

One in 8 pharmacies closed from 2009 to 2015, despite an overall increase in the number of pharmacies during this time.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

The new, standardized, ready-to-use formulation of phenylephrine HCl can help reduce medication errors and improve patient safety.

Top news of the day from across the health care landscape.

At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.

Elexacaftor/ivacaftor/tezacaftor (Trikafta, Vertex Pharmaceuticals) is indicated for patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation.